![](https://investorshub.advfn.com/uicon/250952.png?cb=1618145303)
Monday, May 19, 2014 8:36:32 AM
In the case of PPHM we had NO public offer as did Pfizer with AZ. AZ could react because, possibly and very probably outside its will, Pfizer announced it.
In the case of PPHM we are for sure not talking about any such public offer, at the most an in chambers one covered by legal terms among which certainly non-disclosure to avoid bidding wars.
The interest of PPHM in that area is opposite to the interest of the bidder. Pfizer probably made an offer of which they think AZ share holders cannot refuse or will find it interesting (possibly without understanding the real potential Pfizer is after). AZ management has done what it is there to do, namely evaluate the offer versus potential value and drive any offering close to the real value. Only them can make that assessment.
In that this will be kind of the SAME for PPHM, no matter what an offer is made. I am almost sure that the BEST scientific posters on this board will not really dare to make a statement as to the potential of Bavituximab and as to the turn-around of that potential into market share and related revenue of many years.
That is where ALL PPHM offering shoes will NOT FIT because all potentially interested parties will talk down potential and PPHM will on the other hand explore every corner of it.
As a result I don't think PPHM will get any acquisition offers any more as BP's probably had it with them by now. The road will be one of fragmentation based on geographical-medical discipline-disease.
Oncology, Viral, Inflammatory, Digital Imagine etc are all disciplines that have less or more specialized players. We also see more specialisation lately (eg: GSK - Novartis Oncology/Vaccine exchange) in these disciplines by BPs.
And for disease it is clear that PPHM will want the combination with Chemo/Radio/Immuno depending on what drug or current SOC they work best with for, say, Lung, Liver, Breast and the many others.
Finally geographically will be needed too because the problems and intricacies of clinical trials, commercialisation, pricing, treatment network contacts and relations, cultural and language difference etc will benefit from local partners that know their markets and have all the contacts and networking in place.
I therefore think we can, certainly for now, step away from some general acquisition scenario and watch for fragmented smaller partnerships or as a biggest entity possibly a bavi partial pipeline buyout (say Bavi+Chemo or Bavi+Radio or Bavi+Immo) excluding BetaBodies for which PPHM clearly has some plans.
PPHM files for BETABODIES copyrights
Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.
Recent CDMO News
- Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024 • GlobeNewswire Inc. • 09/03/2024 08:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 08:30:10 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/28/2024 08:34:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/28/2024 08:32:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/28/2024 08:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM